Could a Decades-Old parasite drug help fight pancreatic cancer?

NCT ID NCT05055323

Ongoing Disease control Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This phase I trial tests pyrvinium pamoate, a drug originally used to treat pinworm infections, in people with pancreatic cancer that can be surgically removed. The goal is to find the safest dose and see if it can slow tumor growth. Researchers will monitor side effects and measure how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pyrvinium pamoate, an antiparasitic drug being tested for its ability to slow tumor growth
What this could lead to: If successful, this could point toward a new treatment option for pancreatic cancer that is easier to tolerate than standard chemotherapy.
What could go wrong: This is an early, small phase I trial focused on safety and dosing, so it is too soon to know if the drug will effectively slow tumor growth or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA STAGE 0 PANCREATIC CANCER AJCC V8 STAGE I PANCREATIC CANCER AJCC V8 STAGE IA PANCREATIC CANCER AJCC V8 STAGE IB PANCREATIC CANCER AJCC V8 STAGE II PANCREATIC CANCER AJCC V8 STAGE IIA PANCREATIC CANCER AJCC V8 STAGE IIB PANCREATIC CANCER AJCC V8

Contacts and locations

Show contact details

Locations

Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.